FDA to rule on Moderna's mRNA flu shot — first of its kind to market

The US Food and Drug Administration is preparing to rule on Moderna's mRNA-based influenza vaccine, which could become the first of its kind approved for market. The decision is expected to have wide repercussions across the biotech industry. The move comes amid ongoing public scepticism about mRNA technology fuelled in part by Health Secretary RFK Jr., who has previously questioned its safety.